Small molecule agonists of the relaxin 1 receptor

早期翻译分支（ETB）与NIH和校外研究人员保持了130多个积极合作，促进了整个人类疾病范围内的药物发现工作。这些努力已经导致了数十种高通量筛选和许多药物化学活动，以进一步提高筛选命中值，为我们的合作者和一般研究界提供出版物和各种有前途的小分子探针和先导物。此外，ETB还努力推进一些信息学举措，以更好地利用现有药物和疾病目标信息，并向公众提供易于获取的资源，进一步促进人类疾病新疗法的发展。

The Early Translation Branch (ETB) has maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the ETB has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease. During this period, the collaborative team has worked to characterize the lead molecules using in vitro assays and in vivo models. In vivo pharmacokinetics and efficacy data were obtained for several molecules.